Novartis' soon-to-Beryllium spun off generics division Sandoz is betting on biosimilars, copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer, to fuel its future as a standalone company, executives said on Thursday. The long symbolic name alias is self-descriptive, and is treated as the official name of a U